Literature DB >> 26740382

Recapitulation of metabolic defects in a model of propionic acidemia using patient-derived primary hepatocytes.

Kimberly A Chapman1, Maria S Collado2, Robert A Figler2, Stephen A Hoang2, Allison J Armstrong2, Wanxing Cui3, Michael Purdy4, Michael B Simmers2, Nada A Yazigi3, Marshall L Summar1, Brian R Wamhoff2, Ajit Dash2.   

Abstract

BACKGROUND: Propionic acidemia (PA) is a disorder of intermediary metabolism with defects in the alpha or beta subunits of propionyl CoA carboxylase (PCCA and PCCB respectively) enzyme. We previously described a liver culture system that uses liver-derived hemodynamic blood flow and transport parameters to restore and maintain primary human hepatocyte biology and metabolism utilizing physiologically relevant milieu concentrations.
METHODS: In this study, primary hepatocytes isolated from the explanted liver of an 8-year-old PA patient were cultured in the liver system for 10 days and evaluated for retention of differentiated polarized morphology. The expression of PCCA and PCCB was assessed at a gene and protein level relative to healthy donor controls. Ammonia and urea levels were measured in the presence and absence of amino acid supplements to assess the metabolic consequences of branched-chain amino acid metabolism in this disease.
RESULTS: Primary hepatocytes from the PA patient maintained a differentiated polarized morphology (peripheral actin staining) over 10 days of culture in the system. We noted lower levels of PCCA and PCCB relative to normal healthy controls at the mRNA and protein level. Supplementation of branched-chain amino acids, isoleucine (5mM) and valine (5mM) in the medium, resulted in increased ammonia and decreased urea in the PA patient hepatocyte system, but no such response was seen in healthy hepatocytes or patient-derived fibroblasts.
CONCLUSIONS: We demonstrate for the first time the successful culture of PA patient-derived primary hepatocytes in a differentiated state, that stably retain the PCCA and PCCB enzyme defects at a gene and protein level. Phenotypic response of the system to an increased load of branched-chain amino acids, not possible with fibroblasts, underscores the utility of this system in the better understanding of the molecular pathophysiology of PA and examining the effectiveness of potential therapeutic agents in the most relevant tissue.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ammonia; Hemodynamic flow; Hepatocyte; Organic acidemia; Propionic acidemia; Urea

Mesh:

Substances:

Year:  2015        PMID: 26740382      PMCID: PMC4852394          DOI: 10.1016/j.ymgme.2015.12.008

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  41 in total

1.  Temporal gene expression analysis of monolayer cultured rat hepatocytes.

Authors:  T K Baker; M A Carfagna; H Gao; E R Dow; Q Li; G H Searfoss; T P Ryan
Journal:  Chem Res Toxicol       Date:  2001-09       Impact factor: 3.739

Review 2.  Chronic management and health supervision of individuals with propionic acidemia.

Authors:  V Reid Sutton; Kimberly A Chapman; Andrea L Gropman; Erin MacLeod; Kathy Stagni; Marshall L Summar; Keiko Ueda; Nicholas Ah Mew; Jill Franks; Eddie Island; Dietrich Matern; Loren Peña; Brittany Smith; Tina Urv; Charles Venditti; Anupam Chakarapani
Journal:  Mol Genet Metab       Date:  2011-09-10       Impact factor: 4.797

Review 3.  Induction of drug metabolism: species differences and toxicological relevance.

Authors:  Mark J Graham; Brian G Lake
Journal:  Toxicology       Date:  2008-09-07       Impact factor: 4.221

4.  Tissue specific differences in rate limiting factors of glutamate metabolism in enzyme systems of kidney and liver.

Authors:  E Kun; H H Loh; P Volfin
Journal:  Biochem Biophys Res Commun       Date:  1966-06-13       Impact factor: 3.575

5.  Metabolic differences between mitochondria isolated from various tissues.

Authors:  E Kun; P Volfin
Journal:  Biochem Biophys Res Commun       Date:  1966-06-13       Impact factor: 3.575

Review 6.  Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction.

Authors:  Marcella Martignoni; Geny M M Groothuis; Ruben de Kanter
Journal:  Expert Opin Drug Metab Toxicol       Date:  2006-12       Impact factor: 4.481

Review 7.  Liver tissue engineering in the evaluation of drug safety.

Authors:  Ajit Dash; Walker Inman; Keith Hoffmaster; Samantha Sevidal; Joan Kelly; R Scott Obach; Linda G Griffith; Steven R Tannenbaum
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-10       Impact factor: 4.481

8.  Unusual presentations of propionic acidemia.

Authors:  P T Ozand; M Rashed; G G Gascon; N G Youssef; H Harfi; Z Rahbeeni; S al Garawi; A al Aqeel
Journal:  Brain Dev       Date:  1994-11       Impact factor: 1.961

9.  Propionic acidemia--biochemical studies.

Authors:  V Barash; O Elpeleg; R Amit; S Gottfried; S Yatziv; A Gutman
Journal:  Isr J Med Sci       Date:  1989-02

10.  Inhibition of N-acetylglutamate synthase by various monocarboxylic and dicarboxylic short-chain coenzyme A esters and the production of alternative glutamate esters.

Authors:  M Dercksen; L IJlst; M Duran; L J Mienie; A van Cruchten; F H van der Westhuizen; R J A Wanders
Journal:  Biochim Biophys Acta       Date:  2013-05-02
View more
  8 in total

1.  Inter-relations between 3-hydroxypropionate and propionate metabolism in rat liver: relevance to disorders of propionyl-CoA metabolism.

Authors:  Kirkland A Wilson; Yong Han; Miaoqi Zhang; Jeremy P Hess; Kimberly A Chapman; Gary W Cline; Gregory P Tochtrop; Henri Brunengraber; Guo-Fang Zhang
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-06-20       Impact factor: 4.310

Review 2.  Translating scientific discovery: the need for preclinical models of nonalcoholic steatohepatitis.

Authors:  Abdul M Oseini; Banumathi K Cole; Danny Issa; Ryan E Feaver; Arun J Sanyal
Journal:  Hepatol Int       Date:  2018-01-03       Impact factor: 6.047

3.  Biochemical and anaplerotic applications of in vitro models of propionic acidemia and methylmalonic acidemia using patient-derived primary hepatocytes.

Authors:  M Sol Collado; Allison J Armstrong; Matthew Olson; Stephen A Hoang; Nathan Day; Marshall Summar; Kimberly A Chapman; John Reardon; Robert A Figler; Brian R Wamhoff
Journal:  Mol Genet Metab       Date:  2020-05-11       Impact factor: 4.797

Review 4.  Propionyl-CoA carboxylase - A review.

Authors:  Parith Wongkittichote; Nicholas Ah Mew; Kimberly A Chapman
Journal:  Mol Genet Metab       Date:  2017-10-07       Impact factor: 4.797

5.  A novel small molecule approach for the treatment of propionic and methylmalonic acidemias.

Authors:  Allison J Armstrong; Maria Sol Collado; Brad R Henke; Matthew W Olson; Stephen A Hoang; Christin A Hamilton; Taylor D Pourtaheri; Kimberly A Chapman; Marshall M Summar; Brian A Johns; Brian R Wamhoff; John E Reardon; Robert A Figler
Journal:  Mol Genet Metab       Date:  2021-03-10       Impact factor: 4.204

6.  Generation of isogenic Propionyl-CoA carboxylase beta subunit (PCCB) deficient induced pluripotent stem cell lines.

Authors:  Behshad Pournasr; Stephen A Duncan
Journal:  Stem Cell Res       Date:  2020-08-08       Impact factor: 2.020

7.  Genomic and biochemical analysis of repeatedly observed variants in DBT in individuals with maple syrup urine disease of Central American ancestry.

Authors:  Charles J Billington; Kimberly A Chapman; Eyby Leon; Beatrix W Meltzer; Seth I Berger; Matthew Olson; Robert A Figler; Steve A Hoang; Cui Wanxing; Brian R Wamhoff; M Sol Collado; Kristina Cusmano-Ozog
Journal:  Am J Med Genet A       Date:  2022-07-07       Impact factor: 2.578

8.  Validation of a multicellular tumor microenvironment system for modeling patient tumor biology and drug response.

Authors:  Devin G Roller; Stephen A Hoang; Kristopher D Rawls; Katherine A Owen; Michael B Simmers; Robert A Figler; Julia D Wulfkuhle; Emanuel F Petricoin; Brian R Wamhoff; Daniel Gioeli
Journal:  Sci Rep       Date:  2021-03-10       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.